ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0819

The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar

Joseph Alanaeme1, Sujith Sarvesh1, Jeffrey R Curtis2 and Huifeng Yun2, 1University of Alabama at Birmingham, BIrmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2020

Keywords: Administrative Data, Anti-TNF Drugs, autoimmune diseases, Biologicals, infliximab

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Session Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its biosimilar is safe with no significant loss of efficacy, there are limited real-world data comparing their utilization and adherence patterns. Thus, we evaluated medication adherence among INF biosimilar users and compared them to INF bio-originator users using national administrative data, 2014-2018.

Methods: We established 4 cohorts among patients who had at least one administration or pharmacy claim for INF bio-originator or biosimilar in 2017 Truven Marketscan data, including INF biosimilar naïve users, INF biosimilar prevalent users, INF bio-originator naïve users, and INF bio-originator prevalent users. We evaluate the prior use of INF and other biologics using all available data in 2014-2017 prior to the first INF administration in 2017 (index date).The INF naïve users were defined as no prior use of INF bio-originator or INF biosimilar, whereas prevalent users had any prior use of bio-originator INF but no prior INF biosimilar use. Eligible patients were ≥18 years of age, continuously enrolled with full coverage from 2014 and through follow up. Follow-up started on the index date and ended on the earliest date of death, loss of coverage, or 12/31/2018. For patients who had at least 12 or 18 months of follow-up time, we calculated their proportion of days covered (PDC) at 12 or 18 months. Ongoing analyses are adjusting for important patient characteristics that differ across cohorts.

Results: We identified 96 INF biosimilar naïve users, 223 INF biosimilar prevalent users, 2,149 INF bio-originator naïve users, and 10,970 INF bio-originator prevalent users. The proportion of other biologic use prior to index date and demographic characteristics are similar across different cohorts with mean age of 45 and 60% females. Among patients who had >=12m of follow-up, 43% INF biosimilar naive users, 41.5% INF biosimilar prevalent users, 52% INF bio-originator  naïve users and 73% INF bio-originator  prevalent users continued to be adherent ( >80%) at 12 months. Among patients who had >=18m of follow-up, 48%, 36%, 41%, and 64% user continued to be adherent at 18 months respectively (Table).

Conclusion: The adherence patterns were similar among INF biosimilar naïve, INF biosimilar prevalent, and INF bio-originator naïve users. We found the INF bio-originator prevalent users had the highest adherence within 12 or 18 months of follow-up. However, further studies with large sample size are needed to evaluate the adherence of INF biosimilar users.


Disclosure: J. Alanaeme, None; S. Sarvesh, None; J. Curtis, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Pfizer, 2, 5, Regeneron, 2, 5, Roche, 2, 5, UCB, 2, 5, Gilead Sciences, Inc., 5, Sanofi, 5; H. Yun, Pfizer, 2.

To cite this abstract in AMA style:

Alanaeme J, Sarvesh S, Curtis J, Yun H. The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-adherence-patterns-among-patients-using-infliximab-bio-originator-and-biosimilar/. Accessed May 19, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-adherence-patterns-among-patients-using-infliximab-bio-originator-and-biosimilar/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.